Daily Cardiology Research Analysis
Three impactful cardiology studies stand out today: a double-blind randomized trial (SAFE) shows ramipril and bisoprolol mitigate anthracycline-related subclinical cardiotoxicity; a large Danish all-comer RCT (SORT OUT XI) finds a biolimus-eluting stent is noninferior for target lesion failure but increases definite stent thrombosis; and a recurrent-events analysis from MASTER DAPT supports 1-month DAPT in high-bleeding-risk PCI by reducing total bleeding without increasing total ischemic events
Summary
Three impactful cardiology studies stand out today: a double-blind randomized trial (SAFE) shows ramipril and bisoprolol mitigate anthracycline-related subclinical cardiotoxicity; a large Danish all-comer RCT (SORT OUT XI) finds a biolimus-eluting stent is noninferior for target lesion failure but increases definite stent thrombosis; and a recurrent-events analysis from MASTER DAPT supports 1-month DAPT in high-bleeding-risk PCI by reducing total bleeding without increasing total ischemic events.
Research Themes
- Cardio-oncology cardioprotection during anthracyclines
- Stent selection and safety trade-offs in PCI
- Optimizing DAPT duration in high bleeding risk patients
Selected Articles
1. Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial.
In a multicenter 2×2 factorial RCT of 262 patients receiving anthracyclines, ramipril and bisoprolol each significantly attenuated declines in 3D-LVEF and GLS at 24 months and reduced the incidence of subclinical cardiotoxicity. Findings support early preventive cardioprotection using established agents during chemotherapy.
Impact: This high-quality RCT provides actionable evidence that widely available medications prevent subclinical anthracycline cardiotoxicity, a prevalent and clinically significant problem in cardio-oncology.
Clinical Implications: Consider initiating ACE inhibitor and beta-blocker prophylaxis in eligible patients undergoing anthracycline therapy to reduce subclinical LV dysfunction, with monitoring by 3D-LVEF/GLS.
Key Findings
- At 24 months, declines in 3D-LVEF were smaller with ramipril (-2.1%) and bisoprolol (-2.2%) vs placebo (all P < 0.001).
- Subclinical cardiac damage occurred in 11.4% with ramipril vs 39.3% without, and 9.6% with bisoprolol vs 43.5% without (both P < 0.001).
- GLS results mirrored 3D-LVEF improvements, supporting consistent cardioprotection across imaging markers.
Methodological Strengths
- Multicenter, randomized, double-blind, placebo-controlled 2×2 factorial design
- Objective echocardiographic endpoints (3D-LVEF, GLS) with 24-month follow-up
Limitations
- Primary outcomes are subclinical imaging endpoints rather than hard clinical events
- Modest sample size may limit power for subgroup or interaction analyses
Future Directions: Test whether prophylactic ACE inhibitor/beta-blocker therapy reduces clinical HF events and validate optimal agent/dose/timing across diverse anthracycline regimens and patient risk profiles.
BACKGROUND: Anthracycline-based chemotherapy is a cornerstone in breast cancer treatment but is associated with cardiotoxicity, including subclinical cardiac damage. This study evaluates the efficacy of ramipril and bisoprolol in preventing subclinical cardiac impairment in patients with nonmetastatic breast cancer undergoing anthracycline-based chemotherapy. PATIENTS AND METHODS: The SAFE trial is a multicenter, 2 × 2 factorial, randomized, placebo-controlled, double-blind study involving 262 patients. Participants were allocated to one of four groups: placebo-placebo, ramipril-placebo, bisoprolol-placebo, or ramipril-bisoprolol, administered concurrently with chemotherapy. Subclinical cardiac damage was assessed at 24 months using echocardiographic measures, specifically a ≥10% reduction in three-dimensional left ventricular ejection fraction (3D-LVEF) or global longitudinal strain (GLS). RESULTS: At 24 months, patients receiving ramipril, bisoprolol, or their combination experienced significantly smaller declines in 3D-LVEF compared with placebo (-2.1%, -2.2%, and -3.4%, respectively; all P < 0.001). GLS results were consistent with these findings (P < 0.001). Subclinical cardiac damage occurred in 11.4% of patients receiving ramipril versus 39.3% without ramipril (P < 0.001), and in 9.6% of patients receiving bisoprolol versus 43.5% without bisoprolol (P < 0.001). CONCLUSIONS: Ramipril and bisoprolol significantly reduce the incidence of subclinical cardiac damage in patients with breast cancer undergoing anthracycline-based chemotherapy, thus supporting their use as early prevention cardioprotective strategies.
2. Biolimus-Eluting Biomatrix Stent vs a Dual-Therapy Sirolimus-Eluting Stent in PCI: The SORT OUT XI Randomized Trial.
In 3,136 all-comer PCI patients, the biolimus-eluting Biomatrix Alpha stent was noninferior to a dual-therapy sirolimus-eluting stent for 1-year TLF but had a higher rate of definite stent thrombosis (1.3% vs 0.6%). Cardiac death trended lower with BES but was not statistically significant.
Impact: A large, pragmatic RCT directly informing stent choice shows a safety trade-off: similar efficacy for TLF but higher definite stent thrombosis with the biolimus-eluting platform.
Clinical Implications: When selecting DES in all-comer PCI, weigh the noninferior TLF of BES against its higher definite stent thrombosis; careful patient selection and antithrombotic strategy may be required.
Key Findings
- Primary endpoint: 1-year TLF 4.2% (BES) vs 5.2% (DTS); noninferiority met (P for noninferiority = 0.00002).
- Definite stent thrombosis: 1.3% (BES) vs 0.6% (DTS); incidence rate ratio 2.33 (95% CI 1.07-5.11; P = 0.034).
- Cardiac death: 1.1% (BES) vs 1.9% (DTS), trend but not significant (IRR 0.60; P = 0.08).
Methodological Strengths
- Large, pragmatic all-comer randomized noninferiority design with ITT analysis
- Hard composite endpoint (cardiac death, target lesion MI, TLR) at 1 year
Limitations
- Open-label device trial; potential for procedural/selection biases
- Follow-up limited to 1 year; long-term thrombosis and durability unknown
Future Directions: Assess mechanisms and mitigations for higher stent thrombosis with BES (e.g., strut/polymer interactions, DAPT intensity/duration), and evaluate longer-term outcomes.
BACKGROUND: Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES) is still associated with risk of target lesion failure (TLF). The biolimus A9-eluting Biomatrix Alpha stent (BES), with biodegradable polymer and thin struts, has not been compared head-to-head with another contemporary DES. OBJECTIVES: This study compared 1-year TLF in BES vs dual therapy sirolimus-eluting Combo stent (DTS) in an all-comer population undergoing PCI. METHODS: The trial was conducted in the 3 Western Danish Heart centers (Aalborg, Aarhus, and Odense). The primary composite endpoint was 1-year TLF defined as a composite of cardiac death, target lesion myocardial infarction, or target lesion revascularization. The trial was designed as a noninferiority trial with a noninferiority margin of 2.1%. Data were analyzed by intention-to-treat. RESULTS: From August 14, 2019, to March 19, 2023, 3,136 patients were randomized 1:1 to BES (n = 1,566; 1,891 lesions) vs DTS (n = 1,570; 1,878 lesions). In the intention-to-treat analysis, TLF at 1-year follow-up occurred in 65 patients (4.2%) in the BES group and 82 patients (5.2%) in the DTS group: risk difference: -1.07% (upper limit of 1-sided 90% CI: 0.21%), (P for noninferiority = 0.00002); incidence rate ratio: 0.79 (95% CI: 0.57-1.09; P = 0.15). Cardiac death occurred in 18 patients (1.1%) in the BES group and 30 (1.9%) in the DTS group: incidence rate ratio: 0.60 (95% CI: 0.33-1.07; P = 0.08). Target lesion myocardial infarction occurred in 36 (2.3%) in the BES group and 33 (2.1%) in the DTS group: incidence rate ratio: 1.09 (95% CI: 0.68-1.75; P = 0.73). Definite stent thrombosis occurred in 21 patients (1.3%) in the BES group and 9 (0.6%) in the DTS group: incidence rate ratio: 2.33 (95% CI: 1.07-5.11; P = 0.034). CONCLUSIONS: BES was noninferior to DTS at 1-year follow-up regarding the primary endpoint of TLF. However, BES was associated with significantly increased risk of definite stent thrombosis. (Combo Stent Versus Biomatrix Alpha Stent [SORT OUT XI] NCT03952273).
3. Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patients.
In 4,579 HBR PCI patients, 1-month DAPT had similar total NACEs and MACCEs compared with prolonged DAPT but significantly fewer total bleeding events and fewer cerebrovascular accidents (including strokes) over 335 days using recurrent-event models.
Impact: By analyzing total recurrent events, this study better reflects overall patient burden and supports abbreviated DAPT as a bleeding-sparing strategy without excess ischemia in HBR PCI.
Clinical Implications: For HBR patients after PCI, consider 1-month DAPT to reduce cumulative bleeding and cerebrovascular events while maintaining similar total ischemic event rates.
Key Findings
- Total NACEs: HR 0.95 (95% CI 0.78–1.16; P=0.64) and MACCEs: HR 0.96 (95% CI 0.76–1.20; P=0.69) were similar between abbreviated and prolonged DAPT.
- Total major/CRNM bleeding lower with abbreviated DAPT: HR 0.78 (95% CI 0.64–0.94; P=0.011).
- Fewer cerebrovascular accidents (HR 0.51; P=0.023) and strokes (HR 0.49; P=0.04) with abbreviated DAPT.
Methodological Strengths
- Recurrent-event modeling (Prentice–Williams–Peterson) capturing total event burden
- Large randomized trial dataset with multiple analytic approaches (Andersen–Gill, Poisson)
Limitations
- Post hoc exploratory analysis; potential for residual confounding and multiplicity
- Results apply to HBR patients and specific stent/DAPT regimens; generalizability may be limited
Future Directions: Define patient subgroups benefiting most from abbreviated DAPT and refine duration/intensity considering cerebrovascular protection vs ischemic risk across device and clinical profiles.
BACKGROUND: The effect of dual antiplatelet therapy (DAPT) duration on total events in patients at high bleeding risk (HBR) after percutaneous coronary intervention (PCI) is unclear. OBJECTIVES: This study aimed to evaluate an abbreviated (median duration, 34 days) vs prolonged (median duration, 192 days) DAPT regimen on total events in 4,579 HBR patients from the MASTER DAPT (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen) trial. METHODS: The MASTER DAPT coprimary outcomes at 335 days were as follows: 1) net adverse clinical events (NACEs), the composite of all-cause death, myocardial infarction (MI), stroke, and Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding events; 2) major adverse cardiac and cerebral events (MACCEs), including all-cause death, MI, and stroke; and 3) major or clinically relevant nonmajor bleeding (MCB, type 2, 3, or 5 BARC bleeding). The differences between abbreviated and prolonged DAPT regimens were investigated using the Prentice, Williams, and Peterson model to account for recurrent events. Additional analyses were performed using the Andersen-Gill and Poisson incidence rate models. RESULTS: In the abbreviated DAPT (n = 2,295) arm of the trial, 214 NACEs occurred in 172 patients, compared with 227 NACEs in 182 patients in the prolonged DAPT arm (n = 2,284; HR: 0.95; 95% CI: 0.78-1.16; P = 0.64). A total of 156 MACCEs in 138 patients were observed in the abbreviated DAPT group compared with 160 MACCEs in 138 patients in the prolonged DAPT arm (HR: 0.96; 95% CI: 0.76-1.20; P = 0.69). Fewer total MCBs were observed in the abbreviated DAPT group (180 MCBs in 148 patients) compared with the prolonged DAPT group (240 MCBs in 211 patients, HR: 0.78; 95% CI: 0.64-0.94; P = 0.011). Abbreviated DAPT patients had significantly fewer total cerebrovascular accidents and fewer total strokes compared with the prolonged DAPT group (34 events in 32 patients, HR: 0.51; 95% CI: 0.28-0.91; P = 0.023; and 25 events in 24 patients, HR: 0.49; 95% CI: 0.25-0.98; P = 0.04, respectively). One MACCE in every 5 occurred after a bleeding event, and 1 bleeding event in every 25 occurred after a MACCE, thus emphasizing bleeding as a sentinel event. CONCLUSIONS: A 1-month DAPT duration was associated with similar total NACEs and MACCEs and reduced total bleeding risk compared with prolonged DAPT. Providing a more comprehensive assessment of the total clinical burden, these findings support the use of an abbreviated duration of DAPT after PCI in HBR patients. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen [MASTER DAPT]; NCT03023020).